iShares Global Healthcare ETF CADH (XHC.TO)
63.91
+0.86
(+1.36%)
CAD |
TSX |
Mar 20, 16:00
Key Stats
| Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.66% | -0.10% | 561.73M | 3986.30 |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (All) |
| 0.88% | 12.44% | 51.09M | Upgrade |
Basic Info
| Investment Strategy | |
| XHC seeks to provide long-term capital growth by replicating, to the extent possible, the performance of the S&P Global 1200 Health Care Canadian Dollar Hedged Index, net of expenses. Under normal market conditions, XHC will primarily invest in securities of one or more iShares ETFs and/or equity securities of international issuers participating in the healthcare sector. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | -- |
| Broad Category | Equity |
| Category Name | Sector Equity |
| Category Index | Morningstar Gbl GR CAD |
| Global Category Name | Equity Miscellaneous |
| YCharts Categorization | Other |
| YCharts Benchmark | S&P 500 Total Return (^SPXTR) |
| Prospectus Objective | -- |
| Fund Owner Firm Name | iShares |
| Prospectus Benchmark Index | |
| S&P Gbl 1200 HealthCare Hdg NR CAD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
| Manager Tenure | |
| Not Disclosed | 11.89 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
15
51.09M
-120.22M
Category Low
464.45M
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of February 28, 2023
Risk
Performance Versus Category
As of March 17, 2023. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of March 17, 2023.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| UnitedHealth Group Inc | 6.66% | 476.96 | 1.59% |
| Johnson & Johnson | 6.05% | 153.89 | 0.99% |
| AbbVie Inc | 4.14% | 156.12 | 1.23% |
| Merck & Co Inc | 4.01% | 105.85 | 1.68% |
| Eli Lilly and Co | 3.94% | 333.60 | 1.34% |
| Novo Nordisk A/S Class B | 3.48% | 142.33 | 2.80% |
| Pfizer Inc | 3.42% | 40.81 | 1.77% |
| Thermo Fisher Scientific Inc | 3.26% | 550.57 | 0.59% |
| AstraZeneca PLC | 3.09% | 133.12 | 1.96% |
| Roche Holding AG | 3.01% | 281.17 | 0.52% |
News
Headline
Wire
Time (ET)
Basic Info
| Investment Strategy | |
| XHC seeks to provide long-term capital growth by replicating, to the extent possible, the performance of the S&P Global 1200 Health Care Canadian Dollar Hedged Index, net of expenses. Under normal market conditions, XHC will primarily invest in securities of one or more iShares ETFs and/or equity securities of international issuers participating in the healthcare sector. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | -- |
| Broad Category | Equity |
| Category Name | Sector Equity |
| Category Index | Morningstar Gbl GR CAD |
| Global Category Name | Equity Miscellaneous |
| YCharts Categorization | Other |
| YCharts Benchmark | S&P 500 Total Return (^SPXTR) |
| Prospectus Objective | -- |
| Fund Owner Firm Name | iShares |
| Prospectus Benchmark Index | |
| S&P Gbl 1200 HealthCare Hdg NR CAD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
| Manager Tenure | |
| Not Disclosed | 11.89 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (3-20-23) | 0.88% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 22.50 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of March 17, 2023
Fund Details
| Key Dates | |
| Inception Date | 4/12/2011 |
| Last Annual Report Date | 12/31/2021 |
| Last Prospectus Date | 6/29/2022 |
| Attributes | |
| Index Fund |
|
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds |
|
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |
News
Headline
Wire
Time (ET)